Benefit-Risk Analysis of Buprenorphine for Pain Management

References

• US Department of Health & Human Services. Pain management best practices inter-agency task force report: updates, gaps, inconsistencies, and recommendations 9, 2019. Available from: https://www.hhs.gov/ash/advisory-committees/pain/reports/index.html. Accessed July 11, 2020.
   Google Scholar
• Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–1006. doi:10.15585/mmwr.mm6736a2
   PubMed Web of Science ®Google Scholar
• Rosenquist R. Use of opioids in the management of chronic non-cancer pain. In: Aronson MD, Crowley M, editors. UpToDate. Waltham, MA: UpToDate; 2020.
   Google Scholar
• National Institute on Drug Abuse. Opioid overdose crisis. 2020. Available from: https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis. Accessed September 16, 2020.
   Google Scholar
• Litman RS. Abuse deterrent opioids. In: Fishman S, Crowley M, editors. UpToDate. Waltham, MA: UpToDate; 2020.
   Google Scholar
• Haley DF, Saitz R. The opioid epidemic during the COVID-19 pandemic. JAMA. 2020. doi:10.1001/jama.2020.18543
   Web of Science ®Google Scholar
• Pergolizzi JV Jr., Raffa RB. Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. J Pain Res. 2019;12:3299–3317. doi:10.2147/JPR.S231948
   PubMed Web of Science ®Google Scholar
• Dahan A, Cowan A, Foley K, et al. Buprenorphine – The Unique Opioid Analgesic. Pharmacology and Clinical Application. Thieme Verlagsgruppe.
   Google Scholar
• Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther. 2020;9(1):41–54. doi:10.1007/s40122-019-00143-6
   PubMed Web of Science ®Google Scholar
• Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825–834. doi:10.1093/bja/aei145
   PubMed Web of Science ®Google Scholar
• Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627–632. doi:10.1093/bja/ael051
   PubMed Web of Science ®Google Scholar
• Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13(3):219–230. doi:10.1016/j.ejpain.2008.04.011
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–450. doi:10.1111/j.1533-2500.2010.00378.x
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313. doi:10.1111/j.1533-2500.2008.00204.x
   PubMedGoogle Scholar
• Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274(1):361–372.
   PubMed Web of Science ®Google Scholar
• Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology. 2006;104(6):1232–1242. doi:10.1097/00000542-200606000-00019
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr., Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016;33(10):895–906. doi:10.1002/da.22500
   PubMed Web of Science ®Google Scholar
• Kumar R, Viswanath O, Saadabadi A.Buprenorphine. [Updated 2020 Feb 27].In:StatPearls [Internet].Treasure Island (FL):StatPearls Publishing;2020.Jan-. Available from.https://www.ncbi.nlm.nih.gov/books/NBK459126/.Accessed May 7, 2021.
   Google Scholar
• Buprenex. Package insert. Indivior, Inc.; 2019.
   Google Scholar
• Butrans. Package insert. Purdue Pharma LP; 2019.
   Google Scholar
• Belbuca. Package insert. BioDelivery Sciences International, Inc.; 2019.
   Google Scholar
• Sublocade. Package insert. Indivior, Inc.; 2020.
   Google Scholar
• Subutex. Package insert. Bryant Ranch Prepack; 2009.
   Google Scholar
• Probuphine. Package insert. Titan Pharmaceuticals, Inc.; 2019.
   Google Scholar
• Braeburn. Pipeline. Available from: https://braeburnrx.com/pipeline/.Accessed October 19, 2020.
   Google Scholar
• Nath RP, Upton RA, Everhart ET, et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol. 1999;39(6):619–623. doi:10.1177/00912709922008236
   PubMed Web of Science ®Google Scholar
• Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database Syst Rev. 2015;3:CD009596.
   Google Scholar
• Okkerse P, Alvarez-Jimenez R, Hay JL, et al. No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery. Eur J Pain. 2017;21(3):494–506. doi:10.1002/ejp.943
   Web of Science ®Google Scholar
• Bradley JP. A comparison of morphine and buprenorphine for analgesia after abdominal surgery. Anaesth Intensive Care. 1984;12(4):303–310. doi:10.1177/0310057X8401200403
   Web of Science ®Google Scholar
• Chang KY, Chang WK, Chang WL, et al. Comparison of intravenous patient-controlled analgesia with buprenorphine versus morphine after lumbar spinal fusion–a prospective randomized clinical trial. Acta Anaesthesiol Taiwan. 2006;44(3):153–159.
   Google Scholar
• Kay B. A double-blind comparison of morphine and buprenorphine in the prevention of pain after operation. Br J Anaesth. 1978;50(6):605–609. doi:10.1093/bja/50.6.605
   PubMed Web of Science ®Google Scholar
• Maunuksela EL, Korpela R, Olkkola KT. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anaesth. 1988;60(1):48–55. doi:10.1093/bja/60.1.48
   Web of Science ®Google Scholar
• Mercieri M, Palmisani S, De Blasi RA, et al. Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion: a double-blind, randomized, active-controlled trial. Br J Anaesth. 2017;119(4):792–802. doi:10.1093/bja/aex174
   Web of Science ®Google Scholar
• Oifa S, Sydoruk T, White I, et al. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Clin Ther. 2009;31(3):527–541. doi:10.1016/j.clinthera.2009.03.018
   PubMed Web of Science ®Google Scholar
• Rabinov M, Rosenfeldt FL, McLean AJ. A double-blind comparison of the relative efficacy, side effects and cost of buprenorphine and morphine in patients after cardiac surgery. Aust N Z J Surg. 1987;57(4):227–231. doi:10.1111/j.1445-2197.1987.tb01345.x
   Google Scholar
• Raffa RB, Haidery M, Huang HM, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014;39(6):577–583. doi:10.1111/jcpt.12196
   PubMed Web of Science ®Google Scholar
• Beltrutti D, Niv D, Ben-Abraham R, Di Santo S, Weinbroum AA. Late antinociception and lower untoward effects of concomitant intrathecal morphine and intravenous buprenorphine in humans. J Clin Anesth. 2002;14(6):441–446. doi:10.1016/s0952-8180(02)00397-5
   Web of Science ®Google Scholar
• Jakobs R, Adamek MU, von Bubnoff AC, Riemann JF. Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study. Scand J Gastroenterol. 2000;35(12):1319–1323. doi:10.1080/003655200453692
   Web of Science ®Google Scholar
• Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med. 2014;15(7):1171–1178. doi:10.1111/pme.12386
   PubMed Web of Science ®Google Scholar
• Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379–384. doi:10.1097/01.mjt.0000160935.62883.ff
   PubMedGoogle Scholar
• Edge WG, Cooper GM, Morgan M. Analgesic effects of sublingual buprenorphine. Anaesthesia. 1979;34(5):463–467. doi:10.1111/j.1365-2044.1979.tb06325.x
   PubMed Web of Science ®Google Scholar
• Gaitini L, Moskovitz B, Katz E, Vaisberg A, Vaida S, Nativ O. Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy. Urol Int. 1996;57(4):227–229. doi:10.1159/000282920
   Web of Science ®Google Scholar
• Masson AH. Sublingual buprenorphine versus oral dihydrocodeine in post-operative pain. J Int Med Res. 1981;9(6):506–510. doi:10.1177/030006058100900614
   Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2011;42(6):903–917. doi:10.1016/j.jpainsymman.2011.04.006
   PubMed Web of Science ®Google Scholar
• Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized Phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncol. 2016;27(6):1107–1115. doi:10.1093/annonc/mdw097
   PubMed Web of Science ®Google Scholar
• Desai SN, Badiger SV, Tokur SB, Naik PA. Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: a prospective, randomised clinical study. Indian J Anaesth. 2017;61(3):225–229. doi:10.4103/ija.IJA_208_16
   PubMed Web of Science ®Google Scholar
• Kim HJ, Ahn HS, Nam Y, Chang BS, Lee CK, Yeom JS. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. Eur Spine J. 2017;26(11):2961–2968. doi:10.1007/s00586-017-5213-5
   Web of Science ®Google Scholar
• Lee JH, Kim JH, Kim JH, et al. Efficacy and safety of transdermal buprenorphine versus oral tramadol/acetaminophen in patients with persistent postoperative pain after spinal surgery. Pain Res Manag. 2017;2017:2071494. doi:10.1155/2017/2071494
   Web of Science ®Google Scholar
• Gimbel J, Spierings EL, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a Phase 3, enriched enrollment, randomized withdrawal study. Pain. 2016;157(11):2517–2526. doi:10.1097/j.pain.0000000000000670
   PubMed Web of Science ®Google Scholar
• Hale M, Urdaneta V, Kirby MT, Xiang Q, Rauck R. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–240. doi:10.2147/JPR.S120170
   PubMed Web of Science ®Google Scholar
• Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med. 2016;128(1):1–11. doi:10.1080/00325481.2016.1128307
   PubMed Web of Science ®Google Scholar
• Zimmerman A Conversion of CII opioid to buprenorphine buccal film: a retrospective analysis [304]. AAPM 36th Annual Meeting Scientific Poster Abstracts. 2020:31.
   Google Scholar
• Priestley T, Chappa AK, Mould DR, et al. Converting from Transdermal to buccal formulations of buprenorphine: a pharmacokinetic meta-model simulation in healthy volunteers. Pain Med. 2018;19(10):1988–1996. doi:10.1093/pm/pnx235
   PubMed Web of Science ®Google Scholar
• Webster LR, Hansen E, Cater J, Smith T, Phase A. I placebo-controlled trial comparing the effects of buprenorphine buccal film and oral oxycodone hydrochloride administration on respiratory drive. Adv Ther. 2020;37(11):4685–4696. doi:10.1007/s12325-020-01481-0
   Web of Science ®Google Scholar
• Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors. Available from: https://www.cms.gov/Medicare/Prescription-Drug-coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-Aug-2017.pdf. Accessed May 7, 2021.
   Google Scholar
• Corli O, Montanari M, Deandrea S, Greco MT, Villani W, Apolone G. An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Med. 2012;13(7):897–907. doi:10.1111/j.1526-4637.2012.01408.x
   Web of Science ®Google Scholar
• Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009;31(3):503–513. doi:10.1016/j.clinthera.2009.03.001
   PubMed Web of Science ®Google Scholar
• Leng X, Li Z, Lv H, et al. Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain: an 8-week, randomized, double-blind, double-dummy, multicenter, active-controlled, noninferiority study. Clin J Pain. 2015;31(7):612–620. doi:10.1097/AJP.0000000000000144
   Web of Science ®Google Scholar
• Hale M, Khan A, Kutch M, Once-daily LS. OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505–1518. doi:10.1185/03007995.2010.484723
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R, Oxymorphone ER Study Group. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175–184. doi:10.1016/j.jpain.2006.09.011
   PubMed Web of Science ®Google Scholar
• Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med. 2014;15(6):975–985. doi:10.1111/pme.12377
   PubMed Web of Science ®Google Scholar
• Lazaridou A, Paschali M, Edwards RR, Gilligan C. Is buprenorphine effective for chronic pain? a systematic review and meta-analysis. Pain Med. 2020. doi:10.1093/pm/pnaa089
   Web of Science ®Google Scholar
• US Department of Justice. Drug Enforcement Administration. Drugs of abuse. 2020. Available from: https://www.dea.gov/sites/default/files/2020-04/Drugs%20of%20Abuse%202020-Web%20Version-508%20compliant-4-24-20_0.pdf. Accessed March 29, 2021.
   Google Scholar
• Wightman RS, Perrone J, Scagos R, Krieger M, Nelson LS, Marshall BDL. Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis. J Med Toxicol. 2020. doi:10.1007/s13181-020-00795-3
   Web of Science ®Google Scholar
• Robinson SE. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Rev. 2002;8(4):377–390. doi:10.1111/j.1527-3458.2002.tb00235.x
   PubMedGoogle Scholar
• Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(suppl 2):S13–27. doi:10.1016/s0376-8716(03)00056-5
   PubMed Web of Science ®Google Scholar
• Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice–a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147–1156. doi:10.1185/030079905X53315
   PubMed Web of Science ®Google Scholar
• Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med. 2001;15(4):309–321. doi:10.1191/026921601678320296
   Web of Science ®Google Scholar
• Oxycontin. Package insert. Purdue Pharma L.P.; 2021.
   Google Scholar
• Zohydro. Package insert. Pernix Therapeutics, LLC; 2019.
   Google Scholar
• Kadian. Package insert. Allergan USA, Inc.; 2019.
   Google Scholar
• Nucynta ER. Package insert. Depomed, Inc; 2021.
   Google Scholar
• Wan Y, Corman S, Gao X, Liu S, Patel H, Mody R. Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain. Am Health Drug Benefits. 2015;8(2):93–102.
   Google Scholar
• Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26–30. doi:10.1016/j.jsat.2017.03.006
   PubMed Web of Science ®Google Scholar
• Streltzer J, Davidson R, Goebert D. An observational study of buprenorphine treatment of the prescription opioid dependent pain patient. Am J Addict. 2015;24(4):357–361. doi:10.1111/ajad.12198
   Web of Science ®Google Scholar
• Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209–219. doi:10.1016/j.suponc.2012.05.002
   PubMedGoogle Scholar
• Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomed Pharmacother. 2006;60(7):310–317. doi:10.1016/j.biopha.2006.06.015
   Web of Science ®Google Scholar
• Hallinan R, Byrne A, Agho K, McMahon CG, Tynan P, Attia J. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl. 2009;32(2):131–139. doi:10.1111/j.1365-2605.2007.00824.x
   PubMed Web of Science ®Google Scholar
• Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5(3):684–692. doi:10.1111/j.1743-6109.2007.00702.x
   PubMed Web of Science ®Google Scholar
• Aurilio C, Ceccarelli I, Pota V, et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. Endocr J. 2011;58(12):1071–1078. doi:10.1507/endocrj.ej11-0095
   Web of Science ®Google Scholar
• Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93. doi:10.4088/JCP.13m08725
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57. doi:10.1097/00004714-199502000-00008
   PubMed Web of Science ®Google Scholar
• Serafini G, Adavastro G, Canepa G, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19:8. doi:10.3390/ijms19082410
   Web of Science ®Google Scholar
• Ahmadi J, Jahromi MS. Anxiety treatment of opioid dependent patients with buprenorphine: a randomized, double-blind, clinical trial. Indian J Psychol Med. 2017;39(4):445–449. doi:10.4103/0253-7176.211765
   Google Scholar
• Ducharme J, Moore S. Opioid use disorder assessment tools and drug screening. Mo Med. 2019;116(4):318–324.
   PubMedGoogle Scholar
• Garofoli M. Spuds, screenings & safety: from chips to opioids. PAINWeek. Available from: https://www.painweek.org/media/journal/spuds-screenings-safety-chips-opioids. Accessed October 19, 2020.
   Google Scholar
• Opana ER. Package insert. Endo Pharmaceuticals, Inc; 2019.
   Google Scholar
• Exalgo. Package insert. Mallinckrodt; 2019.
   Google Scholar